Milestone Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference
MONTREAL and CHARLOTTE, N.C., April 07, 2026 -- Milestone
A webcast of the presentation will be available on April 13
If you are interested in meeting with the Milestone team during the conference, please contact your Needham representative.
About Milestone Pharmaceuticals
Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is an emerging commercial-stage biopharmaceutical company advancing innovative cardiovascular medicines to benefit people living with certain heart conditions. Milestone’s lead product is CARDAMYST™ (etripamil) nasal spray, a novel calcium channel blocker, which is FDA approved for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. Etripamil is also in development for the control of symptomatic episodic attacks associated with AFib-RVR.
Contact:
Investor Relations
Media Relations
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Iran offers US a proposal for reopening the Strait Of Hormuz
Canadian Dollar advances as oil prices gain on stalled US–Iran peace talks
ETFs weekly recap – How did Bitcoin, Ethereum, Solana and XRP do this week?


